查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602136

全球幹細胞治療市場：按類型、細胞來源、治療應用、最終用戶分類 - 2025-2030 年預測

Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年幹細胞治療市值為4.3983億美元，預計2024年將達到4.9323億美元，複合年成長率為12.88%，到2030年將達到10.2744億美元。

幹細胞療法代表了醫學創新的一個變革領域，利用未分化的細胞取代體內受損或患病的細胞，治療帕金森氏症、糖尿病和心臟病等多種慢性疾病，為疾病提供了潛在的治療方法。 。幹細胞療法透過針對複雜且以前無法治療的疾病狀態來解決未滿足的醫療需求，這是再生醫學的革命性方法。最終用途涵蓋醫院、研究機構和專科診所，治療領域從腫瘤學到脊髓治療。該市場主要受到幹細胞研究技術進步、人口老化導致慢性病盛行率增加以及公共和私營部門投資增加等因素的顯著推動。隨著個人化醫療越來越被接受，再生治療有可能縮短復原時間並提高生活品質，機會比比皆是。然而，圍繞胚胎幹細胞使用的倫理問題、高昂的治療成本和嚴格的法律規範仍然是市場成長的主要挑戰。也存在局限性，包括治療結果的可變性和長期臨床試驗的複雜性。為了利用市場機會並緩解這些限制，技術創新應專注於開拓具有成本效益的同種異體細胞治療方法和最佳化自體幹細胞應用。需要進一步的研究，包括改進冷凍保存技術和改善細胞分化過程。生物技術公司、學術機構和政府機構之間的合作創造了一個實現突破的生態系統。此外，透過教育宣傳活動提高公眾意識和接受度可以減輕道德擔憂並提高市場滲透率。總體而言，市場格局呈現出一種充滿活力的局面，由巨大的成長潛力支撐，並受到監管、道德和技術挑戰的調節，需要採取永續發展的策略方法。

主要市場統計
基準年[2023] 4.3983億美元
預測年份 [2024] 4.9323 億美元
預測年份 [2030] 10.2744億美元
複合年成長率（%） 12.88%

市場動態：揭示快速發展的幹細胞治療市場的關鍵市場洞察

供需的動態交互作用正在改變幹細胞治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球退化性疾病和癌症患者數量不斷增加
    • 世界各地政府加強對幹細胞治療的力度
    • 擴建幹細胞治療中心和診所
  • 市場限制因素
    • 實施幹細胞療法的困難
  • 市場機會
    • 幹細胞治療的持續進展
    • 幹細胞治療和治療的行銷核准和臨床試驗迅速增加
  • 市場挑戰
    • 使用幹細胞治療的倫理和安全問題

波特五力：駕馭幹細胞治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解幹細胞治療市場的外部影響

外部宏觀環境因素在塑造幹細胞治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解幹細胞治療市場的競爭狀況

幹細胞治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位基質幹細胞治療市場供應商績效評估

FPNV定位矩陣是評估幹細胞治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地退化性疾病和癌症的發生率正在上升
      • 世界各地政府圍繞幹細胞治療的措施增加
      • 擴建幹細胞治療中心和診所
    • 抑制因素
      • 實施幹細胞治療的困難
    • 機會
      • 幹細胞治療的持續進展
      • 幹細胞治療方法的銷售和臨床試驗核准激增
    • 任務
      • 幹細胞治療的倫理與安全問題
  • 市場區隔分析
    • 類型：在慢性病治療中擴大使用同種異體和自體幹細胞療法
    • 細胞來源：AD-MSC 和 BM-MSC 在組織重塑和組織修復的應用越來越多
    • 治療應用：再生醫學在各個治療領域越來越受歡迎
    • 最終用戶：學術研究中心和醫院更多地使用幹細胞治療，提供有效、安全和標準化的治療結果
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章幹細胞治療市場：依類型

  • 同種異體幹細胞療法
  • 自體幹細胞治療

第7章幹細胞治療市場細胞來源

  • 脂肪組織來源的 MSC
  • 骨髓間質幹細胞
  • 胎盤/臍帶來源的 MSC

第8章依治療應用分類的幹細胞治療市場

  • 心血管疾病手術
  • 發炎與自體免疫疾病
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 整形外科和風濕病學
  • 傷口和傷害

第9章幹細胞治療市場：依最終使用者分類

  • 學術研究中心
  • 門診手術中心
  • 生物技術和製藥公司
  • 醫院/診所

第10章美洲幹細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太幹細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲幹細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FUJIFILM投資2億美元用於細胞療法生產
    • FDA 拒絕後 Mesoblast 開始合作進行 SR-aGVHD 試驗
    • Selecta Biosciences 宣布與 Cartesian Therapeutics 合併
    • Takara Bio 與 Fondazione Telethon ETS 簽署 RetroNectin授權合約
    • 拜耳開設第一家細胞療法製造工廠，推動全球再生醫學發展
    • 諾和諾德基金會投資1.35億美元建造細胞治療工廠
    • BioLineRx 宣布 FDA核准APHEXDA（莫替沙福肽）與Filgrastim（G-CSF）聯合用於多發性骨髓瘤患者的造血幹細胞採集和隨後的自體移植
    • BlueRock Therapeutics 和 bit.bio 宣布就基於調節性 T 細胞 (Treg) 的治療方法的發現和製造達成合作和選擇權協議
    • StemCyte與美國領先的免疫細胞治療公司簽署合作協議，為同種異體工程細胞療法提供藥物製造原料
    • CIRM 投資 8,900 萬美元用於幹細胞和基因治療研究
    • 百時美施貴寶在美國開設新的病毒載體生產工廠，增強細胞治療能力
    • 諾和諾德擴大在大波士頓地區的研發足跡
    • Garuda Therapeutics 獲得 6,200 萬美元 B 輪資金籌措，用於推進現成的血液幹細胞技術平台
    • BioCardia 和 CellProthera 加強合作，開發 ProtheraCytes，用於治療歐洲的急性心肌梗塞，並有可能為患者提供早期治療機會
    • ReLive Biotechnologies Ltd. 完成對 Co.Don AG 資產的收購和 SHC主導的A 輪資金籌措，進一步實現成為再生治療全球參與者的雄心

公司名單

  • 4D Molecular Therapeutics, Inc.
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Aurion Biotechnologies
  • Beike Biotechnology Co., Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • CellProthera
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Garuda Therapeutics
  • Holostem Terapie Avanzate Srl
  • Jasper Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Juvena Therapeutics Inc.
  • Kangstem Biotech., Ltd.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Lineage Cell Therapeutics, Inc.
  • Lonza Group AG
  • Mesoblast Ltd.
  • Novo Nordisk A/S
  • Plasticell
  • ReNeuron Group PLC
  • Sartorius CellGenix GmbH
  • SQZ Biotechnologies Company
  • Takara Bio Inc.
  • US Stem Cell Inc
  • Umoja Biopharma
  • Vericel Corporation
Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 439.83 million in 2023, expected to reach USD 493.23 million in 2024, and is projected to grow at a CAGR of 12.88%, to USD 1,027.44 million by 2030.

Stem cell therapy represents a transformative area in medical innovation, where undifferentiated cells are used to replace damaged or diseased cells in the body, offering potential cures for various chronic illnesses such as Parkinson's, diabetes, and heart diseases. The necessity for stem cell therapy arises from its ability to address unmet medical needs by targeting complex and previously untreatable conditions, making it a revolutionary approach in regenerative medicine. Applications range from oncology to spinal cord treatments, with end-use spanning across hospitals, research institutes, and specialized clinics. The market is significantly driven by factors such as technological advancements in stem cell research, an aging population leading to increased prevalence of chronic conditions, and growing investments from both public and private sectors. Opportunities are abundant with the increasing acceptance of personalized medicine and the potential for regenerative treatments to shorten recovery times and enhance life quality. However, ethical concerns surrounding embryonic stem cell use, high treatment costs, and stringent regulatory frameworks remain prominent challenges to market growth. Limitations also include variability in treatment outcomes and the complexity of long-term clinical trials. To capitalize on market opportunities and mitigate these constraints, innovation should focus on developing cost-effective allogenic treatments and optimizing autologous stem cell applications. Further research is warranted in enhancing cryopreservation techniques and improving cell differentiation processes. Collaborations between biotech firms, academic institutions, and government bodies can foster an ecosystem primed for breakthroughs. Moreover, increasing public awareness and acceptance through educational campaigns could alleviate ethical concerns and drive market penetration. Overall, the stem cell therapy market presents a dynamic landscape underpinned by significant growth potential tempered by regulatory, ethical, and technical challenges that necessitate strategic approaches for sustained advancement.

KEY MARKET STATISTICS
Base Year [2023] USD 439.83 million
Estimated Year [2024] USD 493.23 million
Forecast Year [2030] USD 1,027.44 million
CAGR (%) 12.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stem Cell Therapy Market

The Stem Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of degenerative diseases and cancer cases across the world
    • Increasing government initiatives for stem cell therapy across the world
    • Expansion of stem cell therapy centers and clinics
  • Market Restraints
    • Difficulties associated with performing stem cell therapy
  • Market Opportunities
    • Ongoing advancements in stem cell therapy
    • Surging approvals for marketing and clinical trials for stem cell therapies and treatments
  • Market Challenges
    • Ethical and safety issues of stem cell-based therapy

Porter's Five Forces: A Strategic Tool for Navigating the Stem Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stem Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stem Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stem Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stem Cell Therapy Market

A detailed market share analysis in the Stem Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stem Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stem Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Allogeneic Stem Cell Therapy and Autologous Stem Cell Therapy.
  • Based on Cell Source, market is studied across Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, and Placental / Umbilical Cord-Derived MSCs.
  • Based on Therapeutic Application, market is studied across Cardiovascular Diseases Surgeries, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Orthopedics & Rheumatoid, and Wounds & Injuries.
  • Based on End-User, market is studied across Academic & Research Centers, Ambulatory Surgical Centers, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
      • 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
      • 5.1.1.3. Expansion of stem cell therapy centers and clinics
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties associated with performing stem cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in stem cell therapy
      • 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and safety issues of stem cell-based therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
    • 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
    • 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
    • 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Stem Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Allogeneic Stem Cell Therapy
  • 6.3. Autologous Stem Cell Therapy

7. Stem Cell Therapy Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adipose Tissue-Derived MSCs
  • 7.3. Bone Marrow-Derived MSCs
  • 7.4. Placental / Umbilical Cord-Derived MSCs

8. Stem Cell Therapy Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases Surgeries
  • 8.3. Inflammatory & Autoimmune Diseases
  • 8.4. Musculoskeletal Disorders
  • 8.5. Neurological Disorders
  • 8.6. Orthopedics & Rheumatoid
  • 8.7. Wounds & Injuries

9. Stem Cell Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Centers
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Biotechnology & Pharmaceutical Companies
  • 9.5. Hospitals & Clinics

10. Americas Stem Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Stem Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Stem Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
    • 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
    • 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
    • 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
    • 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
    • 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
    • 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
    • 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
    • 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
    • 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
    • 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
    • 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
    • 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
    • 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. Anterogen Co., Ltd.
  • 3. Astellas Pharma Inc.
  • 4. Athersys, Inc.
  • 5. Aurion Biotechnologies
  • 6. Beike Biotechnology Co., Ltd.
  • 7. BrainStorm Cell Therapeutics Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. CellProthera
  • 10. Fate Therapeutics, Inc.
  • 11. Gamida Cell Ltd.
  • 12. Garuda Therapeutics
  • 13. Holostem Terapie Avanzate S.r.l.
  • 14. Jasper Therapeutics, Inc.
  • 15. JCR Pharmaceuticals Co., Ltd.
  • 16. Juvena Therapeutics Inc.
  • 17. Kangstem Biotech., Ltd.
  • 18. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 19. Lineage Cell Therapeutics, Inc.
  • 20. Lonza Group AG
  • 21. Mesoblast Ltd.
  • 22. Novo Nordisk A/S
  • 23. Plasticell
  • 24. ReNeuron Group PLC
  • 25. Sartorius CellGenix GmbH
  • 26. SQZ Biotechnologies Company
  • 27. Takara Bio Inc.
  • 28. U.S. Stem Cell Inc
  • 29. Umoja Biopharma
  • 30. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STEM CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023